Cara Therapeutics (CARA) Misses Q4 EPS by 3c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.43), $0.03 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Keurig Dr Pepper coffee chief to depart ahead of planned split
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM